FDA-approved

Heart & blood

Bivalirudin

Evidence

FDA approved

Class

Direct thrombin inhibitor

/

Bivalirudin

KEY TAKEAWAY

Bivalirudin is a synthetic peptide anticoagulant used during angioplasty and stent procedures. It blocks thrombin directly to prevent clots.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A synthetic copy of a leech-derived anticoagulant

Approved for

Anticoagulation during percutaneous coronary intervention

Key fact

Lowered bleeding compared with heparin plus a platelet inhibitor in heart attack patients

Route

Intravenous infusion

Evidence strength

FDA approved

What it is

What it is

Bivalirudin, sold as Angiomax, is a 20-amino-acid peptide based on hirudin, a clotting inhibitor from medicinal leeches.

How it works

How it works

It binds directly to thrombin, the enzyme that forms clots, and blocks its activity for a short time.

Regulatory status

Regulatory status

The FDA approved bivalirudin in 2000 for use during percutaneous coronary intervention.

What it is used for

What it is used for

Anticoagulation during angioplasty and stenting, including in people who cannot take heparin.

Side effects and risks

Side effects and risks

Bleeding is the main risk. Low blood pressure and allergic reactions are less common.

Citations

Citations

Stone GW et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo